A phase II study of the effects of Herceptin [trastuzumab] in patients with locally advanced HER-2/NEU overexpressing breast cancer.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 May 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012as reported by ClinicalTrials.gov.
- 05 Jan 2009 Planned end date (Sep 2010) added as reported by ClinicalTrials.gov.